Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Toolkit
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Toolkit
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Edition
European
US
Oncology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Expanding Treatment Horizons: Advancements in Key mCRC Populations
August 2025
The following topics were covered during a symposium at the 2025 European Society for Medical Oncology Gastrointestinal Cancers (ESMO-GI)…
Read more
4 Feb 2016
Phase 3 trials of atezolizumab versus standard chemotherapy in PD-L1-selected NSCLC
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD…
4 Feb 2016
LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated adenocarcinoma of the lung
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD…
4 Feb 2016
AZD9291, an EGFR-TKI, for T790M-mediated resistance in non-small cell lung cancer
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD…
4 Feb 2016
LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated lung cancer in first-line
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD…
4 Feb 2016
Oncogene-addicted non-small cell lung cancer
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD…
4 Feb 2016
Quality of life and new therapeutic options for metastatic castration-resistant prostate cancer
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer…
2 Feb 2016
Learn more about the ESMO Asia 2015 Congress
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, ESMO and Congress…
1 Feb 2016
Delivering the promise of immunotherapy for melanoma
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Peter Hersey, MD, PhD…
Loading posts...
« Previous
1
…
16
17
18
19
20
…
48
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View